Treatment | BBP group (%) | Non-BBP group (%) |
---|---|---|
 No | 16 (43.2) | 17 (68.0) |
 Yes (overlapping) | 21 (56.8) | 8 (32.0) |
  TAS-102 | 15 (40.5) | 6 (26.1) |
  REGO | 14 (37.8) | 13 (50.0) |
  CET/PANI | 3 (8.1) | 2 (8.7) |
  Oxaliplatin-based | 2 (5.4) | 2 (8.7) |
  Irinotecan-based | 17 (45.9) | 8 (34.8) |
  Hepatic arterial infusion | 4 (10.8) | 4 (11.1) |
  Others | 4 (10.8) | 4 (16.0) |